When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...

Eli Lilly (LLY) emerges among the top performers in Big Pharma in 2024 with obesity drug success, while Novo Nordisk (NVO) ...

Although Novo will still make a mind-blowing amount of money from its existing obesity drugs in the coming years (its ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Emily Field, Barclays head of European pharmaceutical research, joins 'Squawk Box' to discuss the state of the weight loss drug market, disappointing trial results of Novo Nordisk's experimental ...

U.S. retail investor fund flows into Novo Nordisk surged 32-fold on Friday, as the Danish drugmaker's weaker-than-expected ...

European markets are set to open higher on Tuesday, in a shortened trading session for Christmas Eve. London's FTSE 100 is ...

Health insurers such as UnitedHealth Group and Cigna also recovered some of their recent losses following public controversy about industry practices in the wake of the assassination of UnitedHealth ...

Europe's STOXX 600 ended the day slightly up, driven by a surge in Novo Nordisk shares that helped the healthcare sector. Low trading volumes characterized the day due to holiday anticipation, while ...